Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Study of Eltrekibart in Healthy Subjects
NCT02148627Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jun 2014
- Primary completion
- Feb 2017
- Modality
- IgG Antibodies, PD-1/PD-L1 Inhibitors, Anti-inflammatory mAbs
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of eltrekibart in hidradenitis suppurativa (HS) (3 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Drug-Related Adverse Events at Day 85. Started Jun 2014; status: completed.
02
Drugs
eltrekibart
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NCT02148627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02148627.